Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen.

Henning LN, Carpenter S, Stark GV, Serbina NV.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01590-17. doi: 10.1128/AAC.01590-17. Print 2018 Feb.

2.

Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Savransky V, Shearer JD, Gainey MR, Sanford DC, Sivko GS, Stark GV, Li N, Ionin B, Lacy MJ, Skiadopoulos MH.

Vaccine. 2017 Sep 5;35(37):4952-4959. doi: 10.1016/j.vaccine.2017.07.076. Epub 2017 Jul 31.

3.

Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.

Stark GV, Sivko GS, VanRaden M, Schiffer J, Taylor KL, Hewitt JA, Quinn CP, Nuzum EO.

Vaccine. 2016 Dec 12;34(51):6512-6517. doi: 10.1016/j.vaccine.2016.06.041. Epub 2016 Aug 22.

4.

Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity.

Yamamoto BJ, Shadiack AM, Carpenter S, Sanford D, Henning LN, O'Connor E, Gonzales N, Mondick J, French J, Stark GV, Fisher AC, Casey LS, Serbina NV.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5787-95. doi: 10.1128/AAC.00972-16. Print 2016 Oct.

5.

Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.

Sivko GS, Stark GV, Tordoff KP, Taylor KL, Glaze E, VanRaden M, Schiffer JM, Hewitt JA, Quinn CP, Nuzum EO.

Vaccine. 2016 Dec 12;34(51):6518-6528. doi: 10.1016/j.vaccine.2016.04.048. Epub 2016 May 4.

6.

Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.

Krishnan V, Andersen BH, Shoemaker C, Sivko GS, Tordoff KP, Stark GV, Zhang J, Feng T, Duchars M, Roberts MS.

Clin Vaccine Immunol. 2015 Apr;22(4):430-9. doi: 10.1128/CVI.00690-14. Epub 2015 Feb 11.

7.

Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy.

Teijaro JR, Walsh KB, Long JP, Tordoff KP, Stark GV, Eisfeld AJ, Kawaoka Y, Rosen H, Oldstone MB.

Virology. 2014 Mar;452-453:152-7. doi: 10.1016/j.virol.2014.01.003. Epub 2014 Jan 31.

8.

Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.

Ionin B, Hopkins RJ, Pleune B, Sivko GS, Reid FM, Clement KH, Rudge TL Jr, Stark GV, Innes A, Sari S, Guina T, Howard C, Smith J, Swoboda ML, Vert-Wong E, Johnson V, Nabors GS, Skiadopoulos MH.

Clin Vaccine Immunol. 2013 Jul;20(7):1016-26. doi: 10.1128/CVI.00099-13. Epub 2013 May 8.

9.

Clinical profiles associated with influenza disease in the ferret model.

Stark GV, Long JP, Ortiz DI, Gainey M, Carper BA, Feng J, Miller SM, Bigger JE, Vela EM.

PLoS One. 2013;8(3):e58337. doi: 10.1371/journal.pone.0058337. Epub 2013 Mar 5.

10.

Accumulation of CD11b⁺Gr-1⁺ cells in the lung, blood and bone marrow of mice infected with highly pathogenic H5N1 and H1N1 influenza viruses.

Long JP, Kotur MS, Stark GV, Warren RL, Kasoji M, Craft JL, Albrecht RA, García-Sastre A, Katze MG, Waters KM, Vasconcelos D, Sabourin PJ, Bresler HS, Sabourin CL.

Arch Virol. 2013 Jun;158(6):1305-22. doi: 10.1007/s00705-012-1593-3. Epub 2013 Feb 9.

11.

Pathology and pathophysiology of inhalational anthrax in a guinea pig model.

Savransky V, Sanford DC, Syar E, Austin JL, Tordoff KP, Anderson MS, Stark GV, Barnewall RE, Briscoe CM, Lemiale-Biérinx L, Park S, Ionin B, Skiadopoulos MH.

Infect Immun. 2013 Apr;81(4):1152-63. doi: 10.1128/IAI.01289-12. Epub 2013 Jan 28.

12.

Early indicators of disease in ferrets infected with a high dose of avian influenza H5N1.

Long JP, Vela EM, Stark GV, Jones KJ, Miller ST, Bigger JE.

Sci Rep. 2012;2:972. doi: 10.1038/srep00972. Epub 2012 Dec 13.

13.

Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge.

Fay MP, Follmann DA, Lynn F, Schiffer JM, Stark GV, Kohberger R, Quinn CP, Nuzum EO.

Sci Transl Med. 2012 Sep 12;4(151):151ra126. doi: 10.1126/scitranslmed.3004073.

14.

Development of an inhalational Bacillus anthracis exposure therapeutic model in cynomolgus macaques.

Henning LN, Comer JE, Stark GV, Ray BD, Tordoff KP, Knostman KA, Meister GT.

Clin Vaccine Immunol. 2012 Nov;19(11):1765-75. doi: 10.1128/CVI.00288-12. Epub 2012 Sep 5.

15.

Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment.

Comer JE, Ray BD, Henning LN, Stark GV, Barnewall RE, Mott JM, Meister GT.

Clin Vaccine Immunol. 2012 Sep;19(9):1517-25. doi: 10.1128/CVI.00292-12. Epub 2012 Jul 25.

Supplemental Content

Loading ...
Support Center